

2021-07-16 Meeting notes

Date

16 Jul 2021

Attendees

- Unknown User (hechtt)
- Unknown User (parchmentr)
- Pihl, Todd (NIH/NCI) [C]
- Otridge, John (NIH/NCI) [C]
- Sommers, Connie (NIH/NCI) [E]
- Unknown User (leblancak)
- Kim, Erika (NIH/NCI) [E]
- Regrets:

Goals

- Discuss updates to ICDC and define emerging strategies and priorities

Discussion items

Item	Who	Notes
Introduction for Gina Kuffel	Pihl, Todd (NIH/NCI) [C]	<ul style="list-style-type: none">• Gina comes from Bob Grossman's group and has a background in molecular biology and bioinformatics. She is committed to moving technology forward to make data findable, accessible, interoperable, and reproducible (FAIR)
SC Meeting	Unknown User (parchmentr)	
ICDC Site	Pihl, Todd (NIH/NCI) [C] Kuffel, Gina (NIH/NCI) [C]	<ul style="list-style-type: none">• Data submission• Development priorities<ul style="list-style-type: none">◦ Indicator for dogs participating in multiple studies (dependent on certain pieces of metadata)◦ Widget on project pages to render an overview of the sample profiles◦ Ability to obtain available extended metadata from table downloads in the UI• Site review<ul style="list-style-type: none">◦ Possible evaluation from broader research community• Next release: Sept 13th<ul style="list-style-type: none">◦ ICDC is targeting quarterly releases
ICDC Next Phase	Unknown User (hechtt)	<ul style="list-style-type: none">• Motivate data submitters<ul style="list-style-type: none">◦ Potential to instantiate a MTA in order to provide incentive for data submissions• Potentially involve other institutes to obtain a broader spectrum of data and disease types
Other	Pihl, Todd (NIH/NCI) [C] Kuffel, Gina (NIH/NCI) [C]	<ul style="list-style-type: none">• Reminder: No August meeting

Minutes (Not Verbatim)

TP- Next expected release is Sept. 13th. There is a new multi-study participant feature that illustrates canines that were enrolled in multiple studies, this feature is reliant on metadata, such as the biobank_id to discern this designation. Another feature in progress is the extension of the amount of data available for download through the user interface to be inclusive of all metadata that has been loaded into the data commons, at the moment this extended metadata is only available through the API. Are there other priorities that we should be aware of? ICDC is aiming for quarterly releases.

TH- Do we have any data on the microenvironment, anything other than omics type data?

TP- We do link out to TCGA and other imaging repositories.

TH- We need to capture immune modulators and other types of trials, we need a way of adding that type of data such as treating dogs with various agents, canine biopsies, circulating tumor DNA, etc.

CS- Flow data was considered for ICDC. We talked about getting the numbers, but maybe we need to get the raw data. We didn't address if we would bring in raw flow cytometry data.

TP- Nothing prevents us from getting that type of data into our data model.

CS- If we could maybe provide small financial support that may help people get over the hump and encourage data submission.

TP- Let me talk to Ralph to see if we can find a path to use the honorarium to do this.

TH- We are below on spending, we could use that.

TP- It may come with a ceiling that we need to live with, but we can try to get a mechanism in place.

RP- We do have a mechanism in place that involves a Material Transfer Agreement (MTA), no ceiling on that. We can look into this, it comes out of the legal office, maybe we can set up a conference between the 4 of us

TH- Potentially open this up ICDC up to other institutes, the concern is the amount of data that we currently have, we need to get more data ingested and assess the level of interest from other groups. I have a feeling that other institutes do not have this type of platform.

AL- The National Institute of Aging has an ongoing study on aging canines, there could be immunological data available.

TH- We would need to ensure to tag this type of data so that it is findable by disease type, so that researchers interested in cancer related data could find that data easily.

AL- Dog is a good translational model for cardiovascular disease, diabetes, kidney disease, and others.

JO- Also for narcolepsy.

AL- Additionally, genomic inherited diseases such as renal failure and muscular dystrophy.

AL- We are currently working on osteosarcoma whole genome data from clinical specimens and are looking to obtain canine specific bioinformatic support. We need to establish best practices for how canine data is analyzed

Action items

- ☑ Kuffel, Gina (NIH/NCI) [C] to set up meeting with Pihl, Todd (NIH/NCI) [C] Unknown User (parchmentr) and the legal office to discuss getting a MTA as a potential mechanism to motivate data submitters
- ☑ Kuffel, Gina (NIH/NCI) [C] to connect with CRDC Communications contact to discuss the possibility of launching a usability investigation to better understand user needs